PofoliaShared via Pofolia

Cancer Epidemiology Biomarkers & Prevention· 2014Q1· Review

Epidemiologic and Molecular Prognostic Review of Glioblastoma

Jigisha P. Thakkar, Therese A. Dolecek, Craig Horbinski, Quinn T. Ostrom et al.

Short summary

Glioblastoma multiforme (GBM) incidence is 3.19/100,000, higher in men and white, non-Hispanic individuals, with median survival of 15 months.

AI-generated from the title and abstract; the full text is not read.

Key points

  • Glioblastoma multiforme (GBM) has a median survival of 15 months and an incidence rate of 3.19/100,000.
  • Incidence is higher in men and individuals of white race and non-Hispanic ethnicity.
  • Favorable prognostic factors include younger age, cerebellar location, high performance status, and maximal tumor resection.
  • GBMs are classified into primary and secondary subtypes with distinct genetic pathways, age of onset, and outcomes.
  • Molecular markers are crucial for distinguishing GBM subtypes and have prognostic and predictive value.

AI-generated from the title and abstract; the full text is not read.

Abstract

Glioblastoma multiforme (GBM) is the most common and aggressive primary central nervous system malignancy with a median survival of 15 months. The average incidence rate of GBM is 3.19/100,000 population, and the median age of diagnosis is 64 years. Incidence is higher in men and individuals of white race and non-Hispanic ethnicity. Many genetic and environmental factors have been studied in GBM, but the majority are sporadic, and no risk factor accounting for a large proportion of GBMs has been identified. However, several favorable clinical prognostic factors are identified, including younger age at diagnosis, cerebellar location, high performance status, and maximal tumor resection. GBMs comprise of primary and secondary subtypes, which evolve through different genetic pathways, affect patients at different ages, and have differences in outcomes. We report the current epidemiology of GBM with new data from the Central Brain Tumor Registry of the United States 2006 to 2010 as well as demonstrate and discuss trends in incidence and survival. We also provide a concise review on molecular markers in GBM that have helped distinguish biologically similar subtypes of GBM and have prognostic and predictive value.

The authors' abstract, as published at the source. Cancer Epidemiology Biomarkers & Prevention, 2014 · DOI ↗

TakeawaysPremium
Ask the paperFree account

Continue with a free account

Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.

Continue free on the web

Sign in with Google or Apple; no card needed. You come back to this paper.

On your phone:

Field: Genetics (Medicine)

GeneticsMedicine